Literature DB >> 28680831

A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Sawsan Rashdan1, David E Gerber1,2.   

Abstract

Entities:  

Year:  2017        PMID： 28680831      PMCID： PMC5495191          DOI： 10.21037/tcr.2017.02.12

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  30 in total

1.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

2.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Authors:  Young Lim Choi; Manabu Soda; Yoshihiro Yamashita; Toshihide Ueno; Junpei Takashima; Takahiro Nakajima; Yasushi Yatabe; Kengo Takeuchi; Toru Hamada; Hidenori Haruta; Yuichi Ishikawa; Hideki Kimura; Tetsuya Mitsudomi; Yoshiro Tanio; Hiroyuki Mano
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Crizotinib Resensitization by Compound Mutation.

Authors:  Alice T Shaw; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2016-05-05       Impact factor: 91.245

5.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Authors:  Daniel B Costa; Alice T Shaw; Sai-Hong I Ou; Benjamin J Solomon; Gregory J Riely; Myung-Ju Ahn; Caicun Zhou; S Martin Shreeve; Paulina Selaru; Anna Polli; Patrick Schnell; Keith D Wilner; Robin Wiltshire; D Ross Camidge; Lucio Crinò
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

6.  Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

Authors:  Geoffrey R Oxnard; Maria E Arcila; Camelia S Sima; Gregory J Riely; Juliann Chmielecki; Mark G Kris; William Pao; Marc Ladanyi; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

7.  Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Authors:  Thomas H Marsilje; Wei Pei; Bei Chen; Wenshuo Lu; Tetsuo Uno; Yunho Jin; Tao Jiang; Sungjoon Kim; Nanxin Li; Markus Warmuth; Yelena Sarkisova; Frank Sun; Auzon Steffy; AnneMarie C Pferdekamper; Allen G Li; Sean B Joseph; Young Kim; Bo Liu; Tove Tuntland; Xiaoming Cui; Nathanael S Gray; Ruo Steensma; Yongqin Wan; Jiqing Jiang; Greg Chopiuk; Jie Li; W Perry Gordon; Wendy Richmond; Kevin Johnson; Jonathan Chang; Todd Groessl; You-Qun He; Andrew Phimister; Alex Aycinena; Christian C Lee; Badry Bursulaya; Donald S Karanewsky; H Martin Seidel; Jennifer L Harris; Pierre-Yves Michellys
Journal:  J Med Chem       Date:  2013-06-26       Impact factor: 7.446

8.  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Authors:  Takaaki Sasaki; Jussi Koivunen; Atsuko Ogino; Masahiko Yanagita; Sarah Nikiforow; Wei Zheng; Christopher Lathan; J Paul Marcoux; Jinyan Du; Katsuhiro Okuda; Marzia Capelletti; Takeshi Shimamura; Dalia Ercan; Magda Stumpfova; Yun Xiao; Stanislawa Weremowicz; Mohit Butaney; Stephanie Heon; Keith Wilner; James G Christensen; Michel J Eck; Kwok-Kin Wong; Neal Lindeman; Nathanael S Gray; Scott J Rodig; Pasi A Jänne
Journal:  Cancer Res       Date:  2011-07-26       Impact factor: 12.701

9.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

10.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Authors:  Sai-Hong Ignatius Ou; Jin Seok Ahn; Luigi De Petris; Ramaswamy Govindan; James Chih-Hsin Yang; Brett Hughes; Hervé Lena; Denis Moro-Sibilot; Alessandra Bearz; Santiago Viteri Ramirez; Tarek Mekhail; Alexander Spira; Walter Bordogna; Bogdana Balas; Peter N Morcos; Annabelle Monnet; Ali Zeaiter; Dong-Wan Kim
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544
View more
  4 in total

1.  Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature.

Authors:  Lei Deng; Janaki Sharma; Elizabeth Ravera; Balazs Halmos; Haiying Cheng
Journal:  Lung Cancer (Auckl)       Date:  2018-09-06

Review 2.  Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces.

Authors:  Hao Huang
Journal:  Int J Mol Sci       Date:  2018-11-02       Impact factor: 5.923

3.  Network controllability solutions for computational drug repurposing using genetic algorithms.

Authors:  Victor-Bogdan Popescu; Krishna Kanhaiya; Dumitru Iulian Năstac; Eugen Czeizler; Ion Petre
Journal:  Sci Rep       Date:  2022-01-26       Impact factor: 4.379

Review 4.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group.

Authors:  Alexander I Spira; Mark D Stewart; Suzanne Jones; Elaine Chang; Anitra Fielding; Nicole Richie; Laura S Wood; Michael A Thompson; Lee Jones; Abhilasha Nair; Brandon A Mahal; David E Gerber
Journal:  Clin Cancer Res       Date:  2021-02-09       Impact factor: 13.801
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.